miR-205: A Potential Biomedicine for Cancer Therapy

被引:46
作者
Chauhan, Neeraj [1 ,2 ]
Dhasmana, Anupam [1 ,2 ]
Jaggi, Meena [1 ,2 ]
Chauhan, Subhash C. [1 ,2 ]
Yallapu, Murali M. [1 ,2 ]
机构
[1] Univ Texas Rio Grande Valley, Sch Med, Dept Immunol & Microbiol, Mcallen, TX 78504 USA
[2] Univ Texas Rio Grande Valley, South Texas Ctr Excellence Canc Res, Sch Med, Mcallen, TX 78504 USA
关键词
miRNAs; miR-205; cancer; tumor suppressor; nanoformulation; targeted delivery; MICRORNA EXPRESSION PROFILES; ABNORMAL LIPID-METABOLISM; PROSTATE-CANCER; TUMOR-SUPPRESSOR; CELL-MIGRATION; BREAST-CANCER; MESENCHYMAL TRANSITION; PANCREATIC-CANCER; DOWN-REGULATION; NEOADJUVANT TREATMENT;
D O I
10.3390/cells9091957
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
microRNAs (miRNAs) are a class of small non-coding RNAs that regulate the expression of their target mRNAs post transcriptionally. miRNAs are known to regulate not just a gene but the whole gene network (signaling pathways). Accumulating evidence(s) suggests that miRNAs can work either as oncogenes or tumor suppressors, but some miRNAs have a dual nature since they can act as both. miRNA 205 (miR-205) is one such highly conserved miRNA that can act as both, oncomiRNA and tumor suppressor. However, most reports confirm its emerging role as a tumor suppressor in many cancers. This review focuses on the downregulated expression of miR-205 and discusses its dysregulation in breast, prostate, skin, liver, gliomas, pancreatic, colorectal and renal cancers. This review also confers its role in tumor initiation, progression, cell proliferation, epithelial to mesenchymal transition, and tumor metastasis. Restoration of miR-205 makes cells more sensitive to drug treatments and mitigates drug resistance. Additionally, the importance of miR-205 in chemosensitization and its utilization as potential biomedicine and nanotherapy is described. Together, this review research article sheds a light on its application as a diagnostic and therapeutic marker, and as a biomedicine in cancer.
引用
收藏
页数:29
相关论文
共 217 条
[1]   Predicting effective microRNA target sites in mammalian mRNAs [J].
Agarwal, Vikram ;
Bell, George W. ;
Nam, Jin-Wu ;
Bartel, David P. .
ELIFE, 2015, 4
[2]   The Etiology and Epidemiology of Merkel Cell Carcinoma [J].
Agelli, Maria ;
Clegg, Limin X. ;
Becker, Juergen C. ;
Rollison, Dana E. .
CURRENT PROBLEMS IN CANCER, 2010, 34 (01) :14-37
[3]  
Ali Shadan, 2015, J Cancer Sci Ther, V7, P336
[4]   An estimate of the total number of true human miRNAs [J].
Alles, Julia ;
Fehlmann, Tobias ;
Fischer, Ulrike ;
Backes, Christina ;
Galata, Valentina ;
Minet, Marie ;
Hart, Martin ;
Abu-Halima, Masood ;
Graesser, Friedrich A. ;
Lenhof, Hans-Peter ;
Keller, Andreas ;
Meese, Eckart .
NUCLEIC ACIDS RESEARCH, 2019, 47 (07) :3353-3364
[5]  
[Anonymous], 2002, ADULT PRIMARY LIVER
[6]  
Ardekani Ali M., 2010, Avicenna Journal of Medical Biotechnology, V2, P161
[7]   Treatment of HER2-positive breast cancer: current status and future perspectives [J].
Arteaga, Carlos L. ;
Sliwkowski, Mark X. ;
Osborne, C. Kent ;
Perez, Edith A. ;
Puglisi, Fabio ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (01) :16-32
[8]   Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol [J].
Asghari, Faezeh ;
Haghnavaz, Navideh ;
Shanehbandi, Darioush ;
Khaze, Vahid ;
Baradaran, Behzad ;
Kazemi, Tohid .
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 27 (07) :941-945
[9]  
Badu-Peprah Augustina, 2018, Ghana Med J, V52, P133, DOI [10.4314/gmj.v52i3.5, 10.4314/gmj.v52i4.11]
[10]   miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents [J].
Baumann, Volker ;
Winkler, Johannes .
FUTURE MEDICINAL CHEMISTRY, 2014, 6 (17) :1967-1984